NeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) major shareholder Orbimed Advisors Llc sold 4,674 shares of the business's stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $14.03, for a total transaction of $65,576.22. Following the completion of the sale, the insider now directly owns 3,406,335 shares of the company's stock, valued at approximately $47,790,880.05. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Large shareholders that own more than 10% of a company's stock are required to disclose their sales and purchases with the SEC.
Orbimed Advisors Llc also recently made the following trade(s):
- On Wednesday, May 1st, Orbimed Advisors Llc sold 15,690 shares of NeuroPace stock. The stock was sold at an average price of $14.02, for a total value of $219,973.80.
- On Wednesday, April 24th, Orbimed Advisors Llc sold 1,781 shares of NeuroPace stock. The shares were sold at an average price of $14.06, for a total value of $25,040.86.
- On Monday, April 22nd, Orbimed Advisors Llc sold 24,609 shares of NeuroPace stock. The shares were sold at an average price of $14.05, for a total transaction of $345,756.45.
- On Thursday, April 18th, Orbimed Advisors Llc sold 2,623 shares of NeuroPace stock. The stock was sold at an average price of $14.06, for a total transaction of $36,879.38.
- On Tuesday, April 16th, Orbimed Advisors Llc sold 14,069 shares of NeuroPace stock. The shares were sold at an average price of $14.01, for a total transaction of $197,106.69.
- On Thursday, April 11th, Orbimed Advisors Llc sold 461,899 shares of NeuroPace stock. The stock was sold at an average price of $14.49, for a total transaction of $6,692,916.51.
NeuroPace Price Performance
Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years
From Banyan Hill Publishing | Ad
If you think AI is big, then you have got to check out something I call Imperium…
By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)
Watch my video for all of the details
Shares of NPCE opened at $13.64 on Friday. The firm has a market cap of $391.74 million, a PE ratio of -10.66 and a beta of 2.06. NeuroPace, Inc. has a 52-week low of $3.80 and a 52-week high of $18.15. The company has a debt-to-equity ratio of 2.76, a quick ratio of 5.02 and a current ratio of 5.71. The business's 50 day moving average price is $13.98 and its two-hundred day moving average price is $11.83.
NeuroPace (NASDAQ:NPCE - Get Free Report) last released its earnings results on Tuesday, March 5th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.33) by $0.10. The company had revenue of $18.01 million for the quarter, compared to the consensus estimate of $17.74 million. NeuroPace had a negative net margin of 50.38% and a negative return on equity of 153.76%. On average, equities analysts anticipate that NeuroPace, Inc. will post -1.14 EPS for the current year.
Hedge Funds Weigh In On NeuroPace
A number of institutional investors and hedge funds have recently made changes to their positions in NPCE. Barclays PLC increased its position in NeuroPace by 9,085.6% in the 3rd quarter. Barclays PLC now owns 10,839 shares of the company's stock valued at $105,000 after buying an additional 10,721 shares in the last quarter. EAM Investors LLC bought a new stake in shares of NeuroPace during the third quarter valued at approximately $1,378,000. Kent Lake Capital LLC raised its position in shares of NeuroPace by 285.0% during the third quarter. Kent Lake Capital LLC now owns 574,417 shares of the company's stock worth $5,589,000 after purchasing an additional 425,212 shares during the period. Finally, Citigroup Inc. bought a new position in shares of NeuroPace in the 3rd quarter worth $29,000. Institutional investors own 78.83% of the company's stock.
Wall Street Analyst Weigh In
A number of equities research analysts recently weighed in on the company. Leerink Partnrs restated an "outperform" rating on shares of NeuroPace in a research report on Tuesday, January 30th. Cantor Fitzgerald lifted their target price on shares of NeuroPace from $16.00 to $18.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 6th. Wells Fargo & Company upgraded shares of NeuroPace from an "equal weight" rating to an "overweight" rating and upped their price target for the company from $16.00 to $20.00 in a research report on Thursday, March 14th. Morgan Stanley lifted their price target on shares of NeuroPace from $9.00 to $13.00 and gave the stock an "equal weight" rating in a report on Wednesday, March 6th. Finally, SVB Leerink began coverage on NeuroPace in a research report on Tuesday, January 30th. They set an "outperform" rating and a $22.00 target price for the company. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $15.67.
Check Out Our Latest Stock Report on NeuroPace
About NeuroPace
(
Get Free Report)
NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
